Navigation Links
Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
Date:3/17/2011

South San Francisco, CA, March 18, 2011 Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure. This publication reveals, for the first time in a peer reviewed journal, the mechanism of action for omecamtiv mecarbil and the scientific rationale for directly modulating cardiac contractility as an innovative therapeutic strategy for improving cardiac performance in patients with heart failure.

"It is our honor to have Cytokinetics' novel scientific research into direct modulators of the cardiac contractile apparatus published in this prestigious journal," stated Fady I. Malik, MD, FACC, Cytokinetics' Vice President of Biology and Therapeutics and lead author of this report. "This publication summarizes the pioneering work performed by our dedicated research team that has supported the progression of our lead compound, omecamtiv mecarbil, through clinical development and now into Phase IIb clinical trials, which will be conducted by Amgen in collaboration with Cytokinetics."

The publication titled, "Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure," discusses the potential clinical role for therapies that directly activate cardiac myosin in the treatment of systolic heart failure. The authors recognized that decreased cardiac contractility is a central feature of systolic heart failure and that there is a need for more safe and effective treatment options to improve cardiac contractility. Existing drugs that increase cardiac contractility do so indirectly through signaling cascades but their use is limited by their mechanism-related adverse effects. Omecamtiv mecarbil, a small-molecule, direct
'/>"/>

Contact: Christopher Keenan
ckeenan@cytokinetics.com
415-505-2581
Cytokinetics, Inc.
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
(Date:7/10/2014)... study published today in the journal PNAS (Proceedings ... that time of day and sleep deprivation have a ... crucial when looking at the best time of day ... disease, and for administering medicines effectively. , Researchers from ... Research, London, investigated the links between sleep deprivation, body ...
(Date:7/10/2014)... have shelled out for crude 3-D glasses, polarized ... experience. These basic devices, used to trick the ... soon be rendered obsolete with the introduction of ... researchers. , TAU doctoral students Yuval Yifat, Michal ... holography based on nanoantennas that could be used ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... (Pink Sheets: BSTC.PK) today announced that it sold,200,000 ... private placement,offering to an investment fund, at a ... to the Company of $2,100,000., About BioSpecifics ... biopharmaceutical company that has,developed and licensed injectable collagenase ...
... is seeking nominations for the Third Annual Greater ... March 18, 2008. Those,interested in nominating a company ... The four award categories are: Entrepreneurial, Best ... Award. Nominators will,be asked to submit documentation and ...
... multiplexing module, SANTA ROSA, Calif., Jan. 14 ... provider of optical components for industrial,applications, is to ... technology. The compact LED combining module, which utilizes,proprietary ... medical instrumentation. The ZoroLight LED module will be,on ...
Cached Biology Technology:Bookham to Enter Biomedical Illumination Market 2Bookham to Enter Biomedical Illumination Market 3
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... new study has revealed that mother birds can provide ... sired with their non-social partner (known as extra-pair offspring). ... birds commonly mate with males other than their social ... interloper,s ,extra pair, offspring often outperform their half brothers ...
... Technology for the first time have shown the earliest ... formation of bones, teeth and sea shells. ... capture a three-dimensional image of the nanoparticles that form ... greater understanding of the formation of bones, teeth and ...
... in US women of childbearing age, and is common in ... in the vagina is disrupted and replaced by an overgrowth ... increased risk for a variety of complications, such as preterm ... be prevented. Vitamin D may play a role in BV ...
Cached Biology News:Mothers give interloper's offspring a head start in life 2Mothers give interloper's offspring a head start in life 3Focus on the formation of bones, teeth and shells 2Vitamin D insufficiency linked to bacterial vaginosis in pregnant women 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... provide fast and reliable automation for ... drug development laboratories. Staccato Mini-Workstations offer ... automate basic liquid handling and material ... with either Caliper's time proven CLARA™ ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Fermentation System to achieve high ... and maximum information output 4 ... precision with small-scale requirements provides users ... with E.coli, Pichia pastoris, yeast, fungi ...
Biology Products: